Description
The landscape of type 2 diabetes management is rapidly evolving, particularly with the expanding roles of GLP-1 and GIP/GLP-1 receptor agonists. This program provides a simplified, evidence-based approach to antihyperglycemic agent selection, empowering you to confidently navigate therapeutic choices. Delve into the latest data from key cardiometabolic outcome trials and translate this evidence into practical strategies for your daily practice. Learn to implement a shared decision-making process that aligns with patient priorities; from glycemic targets and weight loss to cardiovascular risk reduction, to optimize cardiometabolic outcomes and enhance patient care.
Course Features:
– 5 video lectures,
– 5 interactive quizzes,
– 1 downloadable resource.
Content Covered:
Module 1: Antihyperglycemic Therapy Selection in Type 2 DiabetesSCORM package,
Module 2: GLP-1 RAs and GIP/GLP-1 RAs Similarities and Differences for People without CVD, CKD or HF,
Module 3: GLP-1 RAs and GIP/GLP-1 RAs in people with type 2 diabetes and at high CV risk.
Sponsorship for this program was provided as an unrestricted educational grant from Eli Lilly Canada Inc.